Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    08-July-2000      
Issue 86 Next Update - 14:00 UTC 08:00 EST    09-July-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya Approved Oncology Drugs

Complete Set Of Oncology Drugs By Name, Manufacturer And Approved Use - By The FDA

This page was last updated on 04-December-2000. Click on the Drug Name to see the Approval Details (data are incomplete, updated data in progress).  Click on the Trade Name to see the Product Label or the   Package Insert (data are incomplete, updated data in progress).  Click on the Manufacturer to see a portfolio of current oncology products.  Please send any errors, omissions, and comments to Send Comment.

Drug Drug Trade Name Approved Use Manufacturer/Distributor
alitretinoin Panretin Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma Ligand Pharmaceuticals
allopurinol Zyloprim Patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy Glaxo-Wellcome
altretamine Hexalen Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination. US Bioscience
amifostine Ethyol To reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer US Bioscience
amifostine Ethyol Reduction of platinum toxicity in non-small cell lung cancer US Bioscience
amifostine Ethyol reduce post-radiation xerostomia for head and neck cancer where the radiation port includes a substantial portion of the parotid glands US Bioscience
anastrozole Arimidex Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. AstraZeneca Pharmaceuticals
anastrozole Arimidex first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. AstraZeneca Pharmaceuticals
arsenic trioxide Trisenox Second line treatment of relapsed or refractory APL following ATRA plus an anthracycline Cell Therapeutic
bexarotene Targretin for the treatment by oral capsule of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Ligand Pharmaceuticals
bexarotene Targretin for the topical treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Ligand Pharmaceuticals
bleomycin Blenoxane Sclerosing agent for the treatment of malignant pleural effusion (MPE) and prevention of recurrent pleural effusions Bristol-Meyers Squibb
busulfan intravenous Busulfex Use in combination with cyclophoshamide as conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia Orphan Medical, Inc
busulfan oral Myleran Chronic Myelogenous Leukemia- palliative therapy Glaxo-Wellcome
capecitabine Xeloda Treatment of metastatic breast cancer resistant to both paclitaxel and an anthracycline containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy may be contraindicated, e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents Hoffmann-La Roche
carboplatin Paraplatin Palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Bristol-Meyers Squibb
carboplatin Paraplatin Initial chemotherapy of advanced ovarian carcinoma in combination with other approved chemotherapeutic agents. Bristol-Meyers Squibb
carmustine with Polifeprosan 20 Implant Gliadel Wafer for use in addition to surgery to prolong survival in patients with recurrent glioblastoma multiforme who qualify for surgery Guilford Pharmaceuticals Inc.
celecoxib Celebrex Reduction of polyp number in patients with the rare genetic disorder of familial adenomatous polyposis Searle
chlorambucil Leukeran Chronic Lymphocytic Leukemia- palliative therapy Glaxo-Wellcome
cisplatin Platinol Metastatic testicular-in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors whoc have already received appropriate surgical and/or radiotherapeutic procedures. An established combination therapy consists of Platinol, Blenoxane and Velbam. Bristol-Meyers Squibb
cisplatin Platinol Metastatic ovarian tumors - in established combination therapy with other approved chemotherapeutic agents: Ovarian-in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Platinol and Adriamycin. Platinol, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Platinol therapy. Bristol-Meyers Squibb
cisplatin Platinol as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy. Bristol-Meyers Squibb
cladribine Leustatin, 2-CdA Treatment of active hairy cell leukemia R.W. Johnson Pharmaceutical Research Institute
cytarabine liposomal DepoCyt Intrathecal therapy of lymphomatous meningitis Skye Pharmaceuticals
daunorubicin liposomal DanuoXome First line cytotoxic therapy for advanced, HIV related Kaposi's sarcoma. Nexstar, Inc.
daunorubicin, daunomycin Daunorubicin Leukemia/myelogenous/monocytic/erythroid of adults/remission induction in acute lymphocytic leukemia of children and adults Bedford Labs
daunorubicin, daunomycin Cerubidine In combination with approved anticancer drugs for induction of remission in adult ALL Wyeth Ayerst Res
dexrazoxane Zinecard Prevention of cardiomyopathy associated with doxorubicin administration Pharmacia & Upjohn Company
docetaxel Taxotere follow up submission for the treatment of locally advanced or metastatic breast cancer which has progressed during anthracycline-based treatment or relapsed during anthracycline-based adjuvant therapy Aventis Pharmaceutical
docetaxel Taxotere Treatment of patients with locally advanced or metastatic breast cancer who have progressed during anthracycline-based therapy or have relapsed during anthracycline-based adjuvant therapy Aventis Pharmaceutical
docetaxel Taxotere locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy Aventis Pharmaceutical
doxorubicin Adriamycin PFS Injection Antibiotic, antitumor agent Pharmacia & Upjohn Company
doxorubicin liposomal Doxil Treatment of AIDS-related Kaposi's sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy. Sequus Pharmaceuticals, Inc.
doxorubicin liposomal Doxil Treatment of metastatic carcinoma of the ovary in patient with disease that is refractory to both paclitaxel and platinum based regimens Sequus Pharmaceuticals, Inc.
Elliott's B Solution Elliott's B Solution Diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma. Orphan Medical, Inc
epirubicin Ellence A component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. Pharmacia & Upjohn Company
estramustine Emcyt palliation of prostate cancer Pharmacia & Upjohn Company
etoposide phosphate Etopophos Management of refractory testicular tumors, in combination with other approved chemotherapeutic agents Bristol-Meyers Squibb
etoposide phosphate Etopophos Management of small cell lung cancer, first-line, in combination with other approved chemotherapeutic agents Bristol-Meyers Squibb
etoposide phosphate Etopophos Management of refractory testicular tumors and small cell lung cancer Bristol-Meyers Squibb
etoposide, VP-16 Vepesid In combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. Bristol-Meyers Squibb
etoposide, VP-16 Vepesid Refractory testicular tumors-in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic and radiotherapeutic therapy. Bristol-Meyers Squibb
exemestane Aromasin treatment of advance breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy Pharmacia & Upjohn Company
fludarabine Fludara Palliative treatment of patients with B-cell lymphocytic leukemia (CLL) who have not responded or have progressed during treatment with at least one standard alkylating agent containing regimen. Berlex Laboratories Inc.
fluorouracil, 5-FU Adrucil prolong survival in combination with leucovorin ICN Puerto Rico
gemcitabine Gemzar Treatment of patients with locally advanced (nonresectable stage II or III) or metastatic (stage IV) adenocarcinoma of the pancreas. Indicated for first-line treatment and for patients previously treated with a 5-fluorouracil-containing regimen. Eli Lilly And Company
gemcitabine Gemzar for use in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer. Eli Lilly And Company
gemtuzumab-ozogamicin Myolotarg CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy. Wyeth Ayerst Res
goserelin acetate Zoladex Implant Palliative treatment of advanced breast cancer in pre- and perimenopausal women AstraZeneca Pharmaceuticals
hydroxyurea Hydrea Capsules Decrease need for transfusions in sickle cell anemia Bristol-Meyers Squibb
idarubicin Idamycin Use in combination with other approved antileukemic drugs for the treatment of acute myeloid leukemia (AML) in adults. Adria Laboratories
idarubicin Idamycin In combination with other approved antileukemic drugs for the treatment of acute non-lymphocytic leukemia in adults Pharmacia & Upjohn Company
ifosfamide IFEX Third line chemotherapy of germ cell testicular cancer when used in combination with certain other approved antineoplastic agents. Bristol-Meyers Squibb
irinotecan Camptosar Treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy. Pharmacia & Upjohn Company
Irinotecan Camptosar first line treatment n combination with 5-FU/leucovorin of metastatic carcinoma of the colon or rectum Pharmacia & Upjohn Company
irinotecan Camptosar Follow up of treatment of metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy Pharmacia & Upjohn Company
letrozole Femara Treatment of advanced breast cancer in postmenopausal women Novartis
leucovorin Leucovorin In combination with fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Lederle Laboratories
levamisole Ergamisol Adjuvant treatment in combination with 5-fluorouracil after surgical resection in patients with Dukes' Stage C colon cancer. Janssen Research Foundation
melphalan, L-PAM Alkeran Systemic administration for palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. Glaxo-Wellcome
mesna Mesnex Prevention of ifosfamide-induced hemorrhagic cystitis Asta Medica
methotrexate Methotrexate osteosarcoma Lederle Laboratories
methoxsalen Uvadex for the use of UVADEX with the UVAR Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment Therakos
mitoxantrone Novantrone For use in combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Immunex Corporation
mitoxantrone Novantrone For use with other approved drugs in the initial therapy for acute nonlymphocytic leukemia (ANLL) in adults. Lederle Laboratories
paclitaxel Paxene treatment of advanced AIDS-related Kaposi's sarcoma after failure of first line or subsequent systemic chemotherapy Baker Norton Pharmaceuticals, Inc
paclitaxel Taxol Treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Bristol-Meyers Squibb
paclitaxel Taxol for use in combination with cisplatin, for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy Bristol-Meyers Squibb
paclitaxel Taxol Treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. Bristol-Meyers Squibb
paclitaxel Taxol First line ovarian cancer with 3 hour infusion Bristol-Meyers Squibb
paclitaxel Taxol for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination therapy. And see notes. Bristol-Meyers Squibb
paclitaxel Taxol New dosing regimen for patients who have failed initial or subsequent chemotherapy for metastatic carcinoma of the ovary Bristol-Meyers Squibb
paclitaxel Taxol second line therapy for AIDS related Kaposi's sarcoma Bristol-Meyers Squibb
paclitaxel Taxol for first-line therapy for the treatment of advanced carcinoma of the ovary in combination with cisplatin Bristol-Meyers Squibb
pamidronate Aredia Treatment of osteolytic bone metastases of breast cancer in conjunction with standard antineoplastic therapy Novartis
Pegademase Adagen (Pegademase Bovine) Enzyme replacement therapy for patients with severe combined immunodeficiency asa result of adenosine deaminase deficiency. Enzon
pentostatin Nipent Single agent treatment for adult patients with alpha interferon refractory hairy cell leukemia. Parke-Davis Pharmaceutical Co.
pentostatin Nipent Single-agent treatment for untreated hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. (Supplement for front -line therapy.) Parke-Davis Pharmaceutical Co.
porfimer sodium Photofrin Use in photodynamic therapy (PDT) for palliation of patients with completely obstructing esophageal cancer, or patients with partially obstructing esophageal cancer who cannot be satisfactorily treated with ND-YAG laser therapy. QLT Phototherapeutics Inc.
porfimer sodium Photofrin for use in photodynamic therapy for treatment of microinvasive endobronchial nonsmall cell lung cancer in patients for whom surgery and radiotherapy are not indicated QLT Phototherapeutics Inc.
porfimer sodium Photofrin for use in photodynamic therapy (PDT) for reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobroncial nonsmall cell lung cancer (NSCLC) QLT Phototherapeutics Inc.
streptozocin Zanosar Antineoplastic agent Pharmacia & Upjohn Company
talc Sclerosol for the prevention of the recurrence of malignant pleural effusion in symptomatic patients Bryan
tamoxifen Nolvadex Metastatic breast cancer in men. AstraZeneca Pharmaceuticals
tamoxifen Nolvadex to reduce the incidence of breast cancer in women at high risk for breast cancer AstraZeneca Pharmaceuticals
tamoxifen Nolvadex In women with DCIS, following breast surgery and radiation, Nolvadex is indicated to reduce the risk of invasive breast cancer. AstraZeneca Pharmaceuticals
tamoxifen Nolvadex As a single agent to delay breast cancer recurrence following total mastectomy and axillary dissection in postmenopausal women with breast cancer (T1-3, N1, M0) AstraZeneca Pharmaceuticals
tamoxifen Nolvadex For use in premenopausal women with metastatic breast cancer as an alternative to oophorectomy or ovarian irradiation AstraZeneca Pharmaceuticals
tamoxifen Nolvadex For use in women with axillary node-negative breast cancer adjuvant therapy. AstraZeneca Pharmaceuticals
tamoxifen Nolvadex Equal bioavailability of a 20 mg Nolvadex tablet taken once a day to a 10 mg Nolvadex tablet taken twice a day. AstraZeneca Pharmaceuticals
tamoxifen Nolvadex to reduce the incidence of breast cancer in women at high risk for breast cancer AstraZeneca Pharmaceuticals
temozolamide Temodar Treatment of adult patients with refractory anaplastic astrocytoma, I.e., patients at first relapse with disease progression on a nitrosourea and procarbazine containing regimen Schering
teniposide, VM-26 Vumon In combination with other approved anticancer agents for induction therapy in patients with refractory childhood acute lymphoblastic leukemia (all). Bristol-Meyers Squibb
topotecan Hycamtin Treatment of patients with metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. SmithKline Beecham
topotecan Hycamtin treatment of small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the phase 3 study) or at least 90 days (in the phase 2 studies) after chemotherapy SmithKline Beecham
toremifene Fareston Treatment of advanced breast cancer in postmenopausal women. Orion Corp.
tretinoin, ATRA Vesanoid Induction of remission in patients with acute promyelocytic leukemia (APL) who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens. Hoffmann-La Roche
valrubicin Valstar for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality Anthra
vinorelbine Navelbine Single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). Glaxo-Wellcome

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.